Does the introduction of an infliximab biosimilar always result in savings for hospitals? A descriptive study using real-world data.
Marko KrsticJean-Christophe DevaudFarshid SadeghipourJoachim MartiPublished in: Health economics review (2024)
The introduction of CT-P13 and the disruption of patient treatment management were not associated with differences in average outpatient and inpatient costs and length of stay, in contrast to the results reported in the rest of the literature. Future research should focus on the cost-effectiveness of non-medical switching policies and the potential benefits for patients.
Keyphrases
- end stage renal disease
- healthcare
- ejection fraction
- systematic review
- computed tomography
- public health
- chronic kidney disease
- contrast enhanced
- magnetic resonance
- palliative care
- magnetic resonance imaging
- mental health
- cross sectional
- machine learning
- risk assessment
- positron emission tomography
- ulcerative colitis
- patient reported
- climate change
- dual energy
- acute care
- replacement therapy